1453211-57-8

Basic information

• Product Name: 2-chloro-5-[(3,5-dimethoxyphenyl)methoxy]pyrimidine
• Synonyms: 2-chloro-5-[(3,5-dimethoxyphenyl)methoxy]pyrimidine
• CAS NO: 1453211-57-8
• Molecular Weight: 280.711
• Mol File: 1453211-57-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-chloro-5-[(3,5-dimethoxyphenyl)methoxy]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-[(3,5-dimethoxyphenyl)methoxy]pyrimidine(1453211-57-8)
• EPA Substance Registry System: 2-chloro-5-[(3,5-dimethoxyphenyl)methoxy]pyrimidine(1453211-57-8)

Safety Data

• Hazardous Substances Data: 1453211-57-8(Hazardous Substances Data)

Upstream product

• 877-88-3 3,5-dimethoxybenzyl bromide 
• 4983-28-2 2-chloropyrimidine-5-ol 
• 192997-46-9 (3,5-dimethoxyphenyl)methyl methanesulfonate 
• 7311-34-4 3,5-dimethoxybenzaldehdye 

Downstream Products

• 1453211-64-7 tert-butyl 4-[4-({5-[(2,6-dichloro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-yl}amino)-3-methoxyphenyl]piperidine-1-carboxylate 
• 1453207-65-2 5-[(2,6-dichloro-3,5-dimethoxybenzyl)oxy]-N-[2-methoxy-4-(piperidin-4-yl)phenyl]pyrimidin-2-amine 
• 1453208-17-7 5-[(2,6-dichloro-3,5-dimethoxybenzyl)oxy]-N-[4-(1-isopropylpiperidin-4-yl)-2-methoxyphenyl]pyrimidin-2-amine 
• 1453210-43-9 5-[(2,6-dichloro-3,5-dimethoxybenzyl)oxy]-N-[3-methoxy-4-(1-methylpiperidin-4-yl)phenyl]pyrimidin-2-amine 
• 1453208-03-1 5-[(3,5-dimethoxyphenyl)methoxy]-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine 

Relevant articles and documents

Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency

Fibroblast growth factor receptor 3 (FGFR3) is an attractive therapeutic target for the treatment of patients with bladder cancer harboring genetic alterations in FGFR3. We identified pyrimidine derivative 20b, which induced tumor regression following ora

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors

A series of 2-aminopyrimidine derivatives were designed and synthesized as highly selective FGFR4 inhibitors. One of the most promising compounds 2n tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymatic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3. The compound selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM. Furthermore, 2n exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, respectively.

NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND

Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.